Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

JonesTrading Keeps Their Buy Rating on Adicet Bio (ACET)

Tipranks - Tipranks - Tue Apr 7, 3:46PM CDT

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Adicet Bio, with a price target of $20.00.

Easter Sale - 70% Off TipRanks

Roy covers the Healthcare sector, focusing on stocks such as CervoMed, Enliven Therapeutics, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of -7.2% and a 32.22% success rate on recommended stocks.

In addition to JonesTrading, Adicet Bio also received a Buy from H.C. Wainwright’s Robert Burns in a report issued on March 23. However, on April 1, TipRanks – OpenAI reiterated a Hold rating on Adicet Bio (NASDAQ: ACET).

See Insiders’ Hot Stocks on TipRanks >>

Based on Adicet Bio’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $30.52 million. In comparison, last year the company had a GAAP net loss of $28.73 million

Read More on ACET:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).